FREE CASE EVALUATION: +1-888-885-2771 Email us: email@example.com
Home - Blog Posts - Roundup Lawsuit - Bayer settles lawsuits from cancer patients over Roundup weed killer in $10 billion agreement
In the wake of thousands of lawsuits brought by cancer patients and their estates, the company that makes Roundup herbicide has settled the majority of current and upcoming lawsuits over $10 billion.
Bayer, The German-based company which acquired the Agrochemical giant Monsanto in 2018, announced the announcement on Wednesday. This comes after many years of lawsuits from people living with cancer who asserted that Roundup resulted in the non-Hodgkin’s lymphoma and claimed that Monsanto was not adequately warning customers about the danger.
Settlement of Roundup litigation throughout the US “will bring closure to approximately 75% of the current Roundup litigation involving approximately 125,000 filed and unfiled claims overall,” Bayer stated in a press release.
“The company will pay $8.8 billion to $9.6 billion to resolve the current Roundup litigation, including an allowance expected to cover unresolved claims and $1.25 billion to support a separate class agreement to address potential future litigation.”
The company has said that future cases could be subject to a class agreement subject to approval by the courts.
Bayer stated that the agreement to settle “contains no admission of liability or wrongdoing.”
In the millions of Roundup lawsuits filed in state or federal courts, three lawsuits have gone to trial: from people living with cancer Dewayne Johnson, Edwin Hardeman and Alva and Alberta Pilliod.
In all of these trials, jurors supported the plaintiffs and said Roundup was a significant cause of cancer in the plaintiffs.
In each case, the jury awarded plaintiffs hundreds of millions ( or billions) of dollars. However, the judges then reduced those amounts because they felt excessive.
Bayer has filed appeals against the verdicts of each of the three trials. The company on Wednesday announced that the requests “will continue through the appeals process and are not covered by the settlement.”
“The company needs to continue these cases as the appeals will provide legal guidance going forward,” Bayer said.
For Roundup, Bayer said it would continue to market the weed killer since it is adamant in its previous claims that it is secure when used according to the directions.
Patients with non-Hodgkin lymphoma began to sue Monsanto in droves following a 2015 World Health Organization report suggesting Glyphosate, the main ingredient in Roundup, could cause cancer.
The report, compiled by the WHO’s International Agency for Research on Cancer, stated that Glyphosate is ” probably carcinogenic to humans.“
However, Monsanto has always maintained that Roundup doesn’t create cancer and has said that they believe that the IARC report is vastly outnumbered by studies that claim Glyphosate is non-hazardous.
“Leading health regulators around the world have repeatedly concluded that Bayer’s glyphosate-based herbicides can be used safely as directed and that glyphosate is not carcinogenic … including more than 100 studies (the) EPA considered relevant to its cancer risk analysis, and more than 800 safety studies overall submitted to regulators,” Bayer has claimed.
The American Cancer Society declared that the cause is unknown for most cases of lymphoma.
However, critics question whether Monsanto enjoyed close relationships with regulators, such as Environmental Protection Agency. Environmental Protection Agency.
An investigation in 2017 by CNN investigation revealed internal emails from Monsanto discussing the communications to the EPA official.
In a letter from 2015, a Monsanto executive stated in an email that an EPA representative at the time suggested that they help stop another agency’s review of Glyphosate. The executive wrote, “ If I can kill this, I should get a medal.”
A Monsanto spokesperson said at the time that the company hasn’t given gifts, paid for or made any other gesture to gain favour with the EPA.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
The fee is free, you only pay when you win!
The fee is free, you only pay when you win. Get Free Consultation from our expert lawyers.
When you see a person you’ve not seen for several months, You’re probably to ask: “Gee, you look great. Have you lost weight?” The most likely answer is Ozempic Wegovy and Mounjaro. Ozempic, as well as Mounjaro, were designed for treating Type 2 diabetes; Wegovy explicitly intended to be a weight-loss drug, making use of the same semaglutide formulation used in Ozempic.
A medical scientist has asked the court to dismiss the lawsuit Johnson & Johnson brought against her for her 2019 research on the link between cosmetic talc and cancer. She argued that her work is reliable and is protected by the freedom of speech rights.
Appeals court OKs ‘common benefit’ fees in Bard IVC filter litigation. Next stop the Supreme Court? – Lawyers representing plaintiffs who have signed agreements to pay a portion of their fee to chiefs of significant multidistrict litigation have to respect those agreements even if they decide to settle disputes outside the process, as per a federal appeals court ruling that week.
The United States Department of Justice and U.S. Navy announced a program of tier-based payouts to those whom the water contamination on Marine Corps Base Camp Lejeune has harmed.
Ozempic Lawsuit: What you need to know – Ozempic (semaglutide) is an injection of 0.5- 2 mg, an injectable prescribed medicine used by type 2 – diabetic patients to lower the risk of heart attack, stroke, or death. Also, some of them are used for weight loss.
Bard Powerport Catheter Lawsuit Updates 2023
1150 NW 72ND AVE TOWER I STE 455
MIAMI, FL 33126
Camp Lejeune Water Lawsuit
AFFF Fire fighter Lawsuit
Hair Relaxer Lawsuit
Tylenol Autism Lawsuit
Worker’s Compensation Lawsuit
Bard PowerPort Catheter Lawsuit
Blog / News Updates
@All rights reserved by Revolts Inc